The U.S. Food and Drug Administration on Tuesday extended the review of Merus NV's gene-targeting cancer therapy to allow sufficient time to review some recent information submitted by the company.

University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...

Modifications can be generated by methods such as gene targeting, nuclear transplantation, transfection of synthetic chromosomes or viral insertion. Selective breeding is not considered a form of ...

Neurogene ( NGNE, Financials) shares fell 35% in Tuesday's pre-market trading following the release of interim results from a ...

Chronic viral hepatitis is the long-term inflammation of the liver. It is caused by hepatitis B, C or D virus particles. Even ...

University of Wisconsin-Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...

EVRY, France, November 12, 2024--(BUSINESS WIRE)--Atamyo Therapeutics a clinical-stage biotechnology company focused on the development of new generation gene therapies targeting muscular dystrophies ...

A study published in Gastroenterology provides novel genetic insights into dietary preferences and opens the possibility of ...

The most important takeaway from the study is that these data suggest that CD47 is an attractive target for drug development.

Since the U.S. and China imposed tit-for-tat tariffs in their trade war during Donald Trump's first presidential term, ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...